Drugs / LA-EP2006
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01735175 | Jun 2012 → May 2013 | breast cancer, chemotherapy-induced toxicity, neutropenia | Sandoz | Completed | No outcome recorded |
| Phase 3 | NCT01516736 | Mar 2012 → Aug 2013 | breast cancer, neutropenia | Sandoz | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LA-EP2006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01516736 ↗ |
| Modality | Protein / enzyme biologic | “LA-EP2006 is a proposed biosimilar that has been developed for pegfilgrastim, a long-acting form of granulocyte colony-stimulating factor” PMID 28637287 ↗ Sep 2017 |
| Route | Subcutaneous | “LA-EP2006 is injected s.c. post chemotherapy application.” NCT01516736 ↗ |